Quest Diagnostics Could Be Your Golden Lab
The 2014 implementation of Obama Care should provide major stimulus for the overall volume of lab work as at least 30 million people become newly covered patients. Industry leader Quest Diagnostics (DGX) is likely to be a big beneficiary.
Quest shares took a big stumble last week after Q4 earnings and revenue came in light. Management claims 6 cents of the fourth quarter disappointment was non-recurring and caused by business lost due to Hurricane Sandy. The stock has retreated from an all-time peak of $64.87 last October. Quest was $62 as recently as Jan. 18. Quest closed at $58.26 Tuesday, an area of solid technical support. The shares got as low as $57.03 intraday....323 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.